Development of Valsartan Floating Matrix Tablets Using Low Density Polypropylene Foam Powder: In vitro and In vivo Evaluation
- 107 Downloads
The main purpose of the study was to develop valsartan floating tablets (VFT) via non-effervescent technique using low density polypropylene foam powder, carbopol, and xanthan gum by direct compression. Before compression, the particulate powdered mixture was evaluated for pre-compression parameters. The prepared valsartan tablets were evaluated for post-compression parameters, swelling index, floating lag time, in vitro buoyancy studies, and in vitro and in vivo X-ray imaging studies in albino rabbits. The result of all formulations for pre- and post-compression parameters were within the limits of USP. FTIR and DSC studies revealed no interaction between the drug and polymers used. The prepared floating tablets had good swelling and floating capabilities for more than 12 h with zero floating lag time. The release of valsartan from optimized formulation NF-2 showed sustained release up to 12 h; which was found to be non-Fickian release. Moreover, the X-ray imaging of optimized formulation (NF-2) revealed that tablet was constantly floating in the stomach region of the rabbit, thereby indicating improved gastric retention time for more than 12 h. Consequently, all the findings and outcomes have showed that developed valsartan matrix tablets could be effectively used for floating drug delivery system.
KEY WORDSvalsartan polypropylene foam powder carbopol floating tablets in vitro and in vivo evaluation
The authors are thankful to Ranbaxy Labs (Hyderabad, India), Membrana GmbH, (Obernburg, Germany), and Shin Etsu Chemicals Co. (Paris, France) for providing the gift sample of valsartan, Accurel®MP1000, carbopol, lactose, and magnesium stearate, respectively.
Compliance with Ethical Standards
Ethical clearance for the research study that was obtained from the Institutional Animal Ethics Committee of East West College of Pharmacy, Bangalore, Karnataka, India constituted for the purpose.
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 1.Gangadharappa HV, Pramod Kumar TM, Shivakumar HG. Gastric floating drug delivery systems. Ind J Pharm Educ Res. 2007;41:295–305.Google Scholar
- 3.Garg T, Kumar A, Rath G, Goyal AK. Gastroretentive drug delivery systems for therapeutic management of peptic ulcer. Crit Rev Ther Drug Carrier Syst. 2014;31:531–57. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2014011104.CrossRefPubMedGoogle Scholar
- 5.Vashisth P, Raghuwanshi N, Srivastava AK, Singh H, Nagar H, Pruthi V. Ofloxacin loaded gellan/PVA nanofibers-synthesis, characterization and evaluation of their gastroretentive/mucoadhesive drug delivery potential. Mater Sci Eng C. 2017;71:611–9. https://doi.org/10.1016/j.msec.2016.10.051.CrossRefGoogle Scholar
- 11.Atyabi F, Sharma HL, Mohammad HA, Fell JT. A novel floating system using ion exchange resins. In Proc Int Symp Control Release Bioact Mater. 1994;21:806–807.Google Scholar
- 14.Meka L, Kesavan B, Chinnala KM, Vobalaboina V, Yamsani MR. Preparation of a matrix type multiple-unit gastro retentive floating drug delivery system for captopril based on gas formation technique: in vitro evaluation. AAPS PharmSciTech. 2008;9:612–9. https://doi.org/10.1208/s12249-008-9090-4.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Alladi KK, Suram R, Bela M, Kiran S, Ramesh V, Narendera Y. Formulation and characterization of clarithromycin controlled release bioadhesive tablets. J Chem Pharm Res. 2011;3:684–90.Google Scholar
- 24.Cargill R, Caldwell LJ, Engle K, Fix JA, Porter PA, Gardner CR. Controlled gastric emptying. 1. Effects of physical properties on gastric residence times of nondisintegrating geometric shapes in beagle dogs. Pharm Res. 1988;5:533–6. https://doi.org/10.1023/A:1015981627525.CrossRefPubMedGoogle Scholar
- 27.Rajeswari RK, Abbulu K, Sudhakar M, Roopakarki, Rajkumar B. Design and in vitro evaluation of modified release Valsartan hydrogels. Int J Drug Deliv. 2011;3:648–60.Google Scholar
- 34.Bader M. Renin-angiotensin aldosterone system. In: Offermanns S, Rosenthal W, editors. Encyclopedic reference of molecular pharmacology. Berlin, Germany: Springer; 2004. p. 810–4.Google Scholar
- 35.Diovan. [Electronic version]. e-CPS. Retrieved 28th December 2009.Google Scholar
- 39.Martin A, Bustamante P, Chum AHC. Physical Pharmacy. New Delhi: BI Waverly Pvt Ltd; 1996. p. 423–52.Google Scholar
- 40.United State Pharmacopeia (USP) XXVI (2003) US Pharmacopoeial Convention, CD Rom version.Google Scholar
- 41.Gupta KR, Wadodkar AR, Wadodkar SG. UV-spectrophotometric methods for estimation of valsartan in bulk and tablet dosage form. Int J ChemTech Res. 2010;2:985–9.Google Scholar
- 43.Salunke PA, Bakliwal SR, Rane BR, Suryawanshi, Pawar SP. Formulation and evaluation of floating microcarriers of an antidiabetic drug a comparative study of effervescent agent. Int J Pharm Tech. 2010;2:496–512.Google Scholar
- 45.Patel HM, Prajapati BG, Patel AK. Controlled release gastroretentive dosage form of verapamil HCl. Int J PharmTech Res. 2009;1:215–21.Google Scholar
- 46.ulla MR, Saisivam S. Floating matrix tablet of losartan potassium by using hydrophilic swelling polymer and natural gum. Turk J Pharm. 2013;10:435–46.Google Scholar
- 50.ICH harmonized tripartite guidelines. Stability testing of new drug substances and products. Q1A (R2). Fed Regist. 2003;68:65717–8.Google Scholar
- 53.Motukuri R, Nagesh P, Venisetty RK. Development and evaluation of gastric retentive floating tablets of Nizatidine. IJPRBS. 2014;3:252–76.Google Scholar
- 58.Gangadharappa HV, Biswas S, Getyala A, Gupta V, Kumar TM. Development, in vitro and in vivo evaluation of novel floating hollow microspheres of rosiglitazone maleate. Pharm Lett. 2011;3:299–316.Google Scholar